{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:37:35Z","timestamp":1787071055892,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy rising from the biliary tree with poor prognosis. We report the feasibility and efficacy of transarterial chemoembolization (TACE) combined with PD-1 inhibitor and apatinib for the treatment of a patient with unresectable ICC. A 70-year-old female presented with intermittent right upper abdominal distension, abdominal pain, and vomiting after eating for more than one month. Enhanced computed tomography (CT) and magnetic resonance imaging (MRI) scan revealed multiple intrahepatic lesions, retroperitoneal lymph node, and left lung metastasis. Based on the patient\u2019s medical history and pathology, the diagnosis was confirmed as locally advanced unresectable ICC. Multimodal therapy was applied to the ICC. The therapy comprised TACE every three months, and a combination regimen of the PD-1 inhibitor camrelizumab and the antiangiogenic agent apatinib. The patient underwent microwave ablation for a lesion on the left lung that had not responded to systemic therapies. Enhanced CT scan after every 2\u20133 months was performed. After several sessions, the primary lesion reduced dramatically in size. At 20 months from diagnosis, the patient was alive, in good condition, and stable. The patient experienced no critical complications and toxicity associated with the administered therapies. This case suggests that treatment with TACE combined with systemic therapy of camrelizumab combined with apatinib may be a safe and effective treatment option for patients with inoperable ICC.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_1697_22","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T12:03:17Z","timestamp":1693224197000},"page":"1055-1060","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Significant response to transarterial chemoembolization combined with PD-1 inhibitor and apatinib for advanced intrahepatic cholangiocarcinoma: A case report and literature review"],"prefix":"10.4103","volume":"19","author":[{"given":"Haitao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiping","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohuan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanshui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.canlet.2016.02.038","article-title":"Multiple cellular origins and molecular evolution of intrahepatic cholangiocarcinoma","volume":"379","author":"Wei","year":"2016","journal-title":"Cancer Lett"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/ijms18020418","article-title":"Targeting angiogenesis in biliary tract cancers:An open option","volume":"18","author":"Simone","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States","volume":"33","author":"Patel","year":"2001","journal-title":"Hepatology"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.tvir.2015.07.006","article-title":"Intrahepatic Cholangiocarcinoma","volume":"18","author":"Padia","year":"2015","journal-title":"Tech Vasc Interv Radiol"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and gemcitabine for advanced biliary tract cancer:A metaanalysis of two randomised trials","volume":"25","author":"Valle","year":"2014","journal-title":"Ann Oncol"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1186\/s12885-018-5081-3","article-title":"Comparison of the efficacy and safety of transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma","volume":"18","author":"Chen","year":"2018","journal-title":"BMC Cancer"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","article-title":"Updated use of TACE for hepatocellular carcinoma treatment:How and when to use it based on clinical evidence","volume":"72","author":"Raoul","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.crad.2010.11.002","article-title":"Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma","volume":"66","author":"Park","year":"2011","journal-title":"Clin Radiol"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.clcc.2016.07.007","article-title":"The potential value of immunotherapy in colorectal cancers:Review of the evidence for programmed death-1 inhibitor therapy [J]","volume":"15","author":"Toh","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.eururo.2017.06.012","article-title":"Systematic review of immune checkpoint inhibition in urological cancers","volume":"72","author":"Rijnders","year":"2017","journal-title":"Eur Urol"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","article-title":"Cancer immunotherapy:Opportunities and challenges in the rapidly evolving clinical landscape","volume":"81","author":"Emens","year":"2017","journal-title":"Eur J Cancer"},{"key":"R13-20241021","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT):A multicentre, randomised, open-label, phase 3 study","volume":"21","author":"Huang","year":"2020","journal-title":"Lancet Oncol"},{"key":"R14-20241021","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN1st):A multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"R15-20241021","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0640","article-title":"Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung cancer","volume":"7","author":"Zhao","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"R16-20241021","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.4103\/jcrt.jcrt_1310_21","article-title":"Clinical observation of local intervention combined with camrelizumab and apatinib in the treatment of metastatic soft-tissue sarcoma","volume":"17","author":"Li","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"R17-20241021","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4103\/jcrt.JCRT_221_18","article-title":"Expert consensus workshop report:Guidelines for thermal ablation of primary and metastatic lung tumors (2018 edition)","volume":"14","author":"Ye","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"R18-20241021","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","article-title":"Intrahepatic cholangiocarcinoma:Rising frequency, improved survival, and determinants of outcome after resection","volume":"248","author":"Endo","year":"2008","journal-title":"Ann Surg"},{"key":"R19-20241021","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"R20-20241021","first-page":"6877","article-title":"Transcatheter arterial embolic therapies for hepatocellular carcinoma:A literature review","volume":"34","author":"Nishikawa","year":"2014","journal-title":"Anticancer Res"},{"key":"R21-20241021","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/S0959-8049(16)30326-4","article-title":"Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer:Interim results of KEYNOTE-028","volume":"51","author":"Bang","year":"2015","journal-title":"Eur J Cancer"},{"key":"R22-20241021","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.csbj.2019.03.006","article-title":"Application of PD-1 blockade in cancer immunotherapy","volume":"17","author":"Wu","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"R23-20241021","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1038\/onc.2012.617","article-title":"Intrahepatic cholangiocarcinoma:Pathogenesis and rationale for molecular therapies","volume":"32","author":"Sia","year":"2013","journal-title":"Oncogene"},{"key":"R24-20241021","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-Pd-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer:An open-label, dose escalation and expansion study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R25-20241021","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"R26-20241021","doi-asserted-by":"crossref","first-page":"288","DOI":"10.14218\/JCTH.2016.00058","article-title":"Impact of different embolic agents for transarterial chemoembolization (TACE) procedures on systemic vascular endothelial growth factor (VEGF) levels","volume":"4","author":"Schicho","year":"2016","journal-title":"J Clin Transl Hepatol"},{"key":"R27-20241021","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.4103\/jcrt.JCRT_1030_19","article-title":"Transcatheter arterial chemoembolization combined with low-dose apatinib in the treatment of unresectable hepatocellular carcinoma in elderly patients:Efficacy and safety","volume":"16","author":"Liu","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"R28-20241021","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R29-20241021","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4103\/jcrt.JCRT_101_20","article-title":"Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI):A novel treatment for patients with advanced hepatocellular carcinoma","volume":"16","author":"Meng","year":"2020","journal-title":"J Cancer Res Ther"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1697_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:50Z","timestamp":1787067650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1697_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1697_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"2022-08-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}